NCT05986682Completed
Real-World Analysis of Belantamab Mafodotin Care Patterns in Patients With Relapsed and/or Refractory Multiple Myeloma
Source: ClinicalTrials.gov · Last updated 3 Feb 2025
Brief summary (registry, in English)
The purpose of this study is to describe the real-world use of Belantamab Mafodotin - blmf (BLENREP) and associated patterns of care, including dosing and dose modification, eye care specialist visits, associated healthcare utilization, and clinical outcomes in patients with relapsed and/or refractory multiple myeloma (RRMM) seen in the Duke Cancer Institute (DCI) clinics.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 30 (actual)
- First submitted
- 24 Jul 2023
- Start date
- 18 Sept 2023
- Primary completion date
- 7 Nov 2023
- Lead sponsor
- Duke University
- Diseases
- Multiple myeloma
- NCT number
- NCT05986682
What you commit to
- Study type: Observational
- Participants enrolled: 30
- From 18 Sept 2023 to the primary completion date, 7 Nov 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Age
- Age \> 89 years of age as of start of index therapy
Other
- Patients who were included in any clinical trial for BLENREP including expanded access clinical trials
Who the study is looking for
- Age \> 18 years of age as of start of treatment with BLENREP
- Patients with a corresponding diagnosis code consistent with multiple myeloma seen at Duke.
- Patients with a record of starting treatment with BLENREP for RRMM between August 5, 2020 and November 22, 2022.
- Patients having healthcare encounters at Duke Cancer Institute (DCI) for at least 1-month after start of Blenrep treatment.
Age in the registry: 18 years to 89 years · Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Duke University Medical Center Coordinator of this site? Confirm its status | Durham | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.